01—Abstract
Summary
Summary of the 8-K filed November 6, 2025. Cited figures are marked; the original filing is the authoritative source.
BeOne Medicines (ONC) reported strong third quarter 2025 results, with total revenue rising 41% year over year to $1.41 billiona and product revenue reaching $1.40 billion.
Growth was driven primarily by BRUKINSA (zanubrutinib), whose global sales rose 51% to roughly $1.0 billionb, with U.S. BRUKINSA sales of $739 million (+47%) and European sales of $163 million (+68%). TEVIMBRA (tislelizumab) sales grew 17% to $191 million. Profitability improved sharply: GAAP net income was $124.8 million (diluted EPS of $1.09 per ADS) versus a $121.4 million loss a year earlier, and non-GAAP diluted EPS was $2.65 per ADS.
Gross margin expanded to 85.9% on a GAAP basis, and free cash flow was $354 millionc, compared with $55 million in the prior-year quarter. Management raised its full-year 2025 total revenue guidance to $5.1–$5.3 billion from $5.0–$5.3 billion, primarily by lifting the low end. GAAP operating expense guidance was narrowed to $4.1–$4.3 billion from $4.1–$4.4 billion.
Gross margin, operating income, and free cash flow guidance were left unchanged. Cash, cash equivalents and restricted cash rose to $4.1 billiond at quarter-end, partly reflecting an $885 million royalty financing liability tied to a Royalty Pharma agreement covering Amgen's IMDELLTRA sales outside China, worth up to $950 million. The pipeline update points to several near-term catalysts, including a BGB-16673 (BTK degrader) data readout for a potential accelerated approval submission in CLL in 1H 2026, a Phase 3 head-to-head trial versus pirtobrutinib, and sonrotoclax Phase 3 enrollment starting in 1H 2026.
Zanidatamab Phase 3 PFS data are expected in 2H 2025. Investors should note that the quarter benefited from lower in-process R&D upfront and milestone payments, and that GAAP figures still include substantial share-based compensation. Non-GAAP metrics exclude these items, so the gap between GAAP and adjusted results remains large.
02—Key points
Key Highlights
- Total revenue rose 41% to $1.41B in Q3 2025, and nine-month revenue rose 43% to $3.84B.
- BRUKINSA global sales reached about $1.0B (+51%), with U.S. sales of $739M (+47%) and Europe sales of $163M (+68%).
- GAAP net income turned positive at $124.8M (diluted EPS $1.09/ADS), versus a $121.4M loss in Q3 2024; non-GAAP diluted EPS was $2.65/ADS.
- GAAP gross margin improved to 85.9% (from 82.8%), and free cash flow reached $354M (vs. $55M a year earlier).
- Full-year 2025 total revenue guidance was raised at the low end to $5.1–$5.3B, and GAAP operating expense guidance was narrowed to $4.1–$4.3B.
- Cash rose to $4.1B at September 30, 2025, supported in part by an $885M royalty financing liability tied to the Royalty Pharma IMDELLTRA royalty deal (up to $950M).
- Key near-term catalysts include the BGB-16673 CLL data readout (1H 2026), sonrotoclax Phase 3 starts (1H and 2H 2026), and zanidatamab Phase 3 PFS readout (2H 2025).
03—Questions
Frequently Asked Questions
What drove the revenue growth in the quarter?
Growth came mainly from BRUKINSA, with U.S. sales up 47% and European sales up 68%, reflecting strong demand across indications and a modest benefit from net pricing. TEVIMBRA sales rose 17%, and in-licensed products from Amgen also contributed.
Is BeOne now solidly profitable on a GAAP basis?
Q3 2025 GAAP net income was $124.8M, a sharp improvement from the prior-year loss. Nine-month GAAP net income was $220.4M, compared with a $492.9M loss a year earlier. Investors should still note that GAAP results include about $141M of quarterly share-based compensation, and the non-GAAP adjusted figures are substantially higher.
Did guidance change, and what does it imply?
Total revenue guidance was narrowed upward to $5.1–$5.3B from $5.0–$5.3B. GAAP operating expense guidance was narrowed to $4.1–$4.3B from $4.1–$4.4B. Gross margin, GAAP operating income, and free cash flow guidance were unchanged, and the guidance excludes unannounced business development activity.
What is the Royalty Pharma transaction, and how does it affect the balance sheet?
BeOne agreed to sell royalty rights on worldwide IMDELLTRA sales (excluding China) for up to $950M. The balance sheet shows an $885M royalty financing liability at September 30, 2025, and the transaction contributed to a $961M quarterly financing cash inflow. Because this is a financing liability rather than revenue, it does not improve reported operating results.
What clinical and regulatory catalysts should investors watch?
Key items include a BGB-16673 (BTK CDAC) data readout for a potential accelerated approval submission in R/R CLL in 1H 2026, the first-line TEVIMBRA gastric cancer approval decision in Japan (2H 2026), and sonrotoclax Phase 3 enrollment starting in 1H 2026 with BRUKINSA, along with a Phase 3 trial versus pirtobrutinib already underway. Zanidatamab Phase 3 PFS data from the Herizon GEA-301 trial are expected in 2H 2025.
04—Continue